Covariates related to methotrexate clearance in a multivariate general linear model
| Factor . | Direction . | P* . | R2* . | P† . | R2† . |
|---|---|---|---|---|---|
| 24-hour infusion (vs 4 hour) | 24-hour higher | < 2 × 10−16 | 38% | < 2 × 10−16 | 38% |
| DI (vs no DI) | DI lower | .0010 | 0.5% | .0022 | 0.4% |
| Age | Older lower | 9 × 10−7 | 1.1% | 7 × 10−7 | 1.2% |
| Sex | Boys greater | .00028 | 0.6% | .00027 | 0.5% |
| rs4149056 T > C | C lower | 2.1 × 10−11 | 2% |
| Factor . | Direction . | P* . | R2* . | P† . | R2† . |
|---|---|---|---|---|---|
| 24-hour infusion (vs 4 hour) | 24-hour higher | < 2 × 10−16 | 38% | < 2 × 10−16 | 38% |
| DI (vs no DI) | DI lower | .0010 | 0.5% | .0022 | 0.4% |
| Age | Older lower | 9 × 10−7 | 1.1% | 7 × 10−7 | 1.2% |
| Sex | Boys greater | .00028 | 0.6% | .00027 | 0.5% |
| rs4149056 T > C | C lower | 2.1 × 10−11 | 2% |
DI indicates delayed intensification; direction, direction of association with clearance, ie, those receiving the 24-hour infusion had greater clearance than those receiving the 4-hour infusion; P, association of the factor with average methotrexate clearance based on a multivariate analysis; and R2, the amount of interindividual variation explained by each factor.
P and R2 values for the multivariate model, including infusion length, use of DI, age, and sex.
P and R2 value for the multivariate model and also including the rs4149056 genotype.